×
Back to Agenda
Session 4: Special Safety Considerations in Benefit-Risk Equipoise of Allogeneic Chimeric Antigen Receptor T (alloCAR-T) Cell Therapies
Session Chair(s)
William Gregory, PHD
Senior Director, Safety and Risk Management, Pfizer Inc, United States
Session 4: Special Safety Considerations in Benefit-Risk Equipoise of Allogeneic Chimeric Antigen Receptor T (alloCAR-T) Cell Therapies
Speaker(s)
Peter F. Bross, MD
Medical Review Officer OTAT, CBER, FDA, United States
Speaker
William Gregory, PHD
Senior Director, Safety and Risk Management, Pfizer Inc, United States
Speaker
Have an account?